Cargando…

Low Risk of Hyperprogression with First-Line Chemoimmunotherapy for Advanced Non-Small Cell Lung Cancer: Pooled Analysis of 7 Clinical Trials

BACKGROUND: Monotherapy immune checkpoint inhibitor (ICI) used in second- or later-line settings has been reported to induce hyperprogression. This study evaluated hyperprogression risk with ICI (atezolizumab) in the first-, second-, or later-line treatment of advanced non–small cell lung cancer (NS...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Lee X, Cappuzzo, Federico, Matos, Ignacio, Socinski, Mark A, Hopkins, Ashley M, Sorich, Michael J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Lung Cancer
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10078909/ https://www.ncbi.nlm.nih.gov/pubmed/36905578 http://dx.doi.org/10.1093/oncolo/oyad043

Ejemplares similares

Systemic therapy options following first-line chemoimmunotherapy in small-cell lung cancer
por: Pacheco, Jose M.
Publicado: (2020)

Clinical Outcomes of Afatinib Versus Osimertinib in Patients With Non-Small Cell Lung Cancer With Uncommon EGFR Mutations: A Pooled Analysis
por: Wang, Chunsheng, et al.
Publicado: (2023)

PD-1 inhibitor plus chemotherapy versus bevacizumab plus chemotherapy in patients with advanced non-squamous non-small-cell lung cancer: a pooled analysis of three randomised trials
por: Meng, Xiangjiao, et al.
Publicado: (2022)

A Prospective Study of Apatinib in Patients with Extensive‐Stage Small Cell Lung Cancer After Failure of Two or More Lines of Chemotherapy
por: Liu, Yutao, et al.
Publicado: (2020)

ALK Inhibitors or Chemotherapy for Third Line in ALK-positive NSCLC? Real-world Data
por: Moskovitz, Mor, et al.
Publicado: (2022)

Stage I and II Small-Cell Lung Cancer—New Challenge for Surgery
por: Doerr, Fabian, et al.
Publicado: (2022)

RET Fusion-Positive Non-small Cell Lung Cancer: The Evolving Treatment Landscape
por: Novello, Silvia, et al.
Publicado: (2023)

Survival of patients with small cell lung cancer undergoing lung resection in England, 1998–2009
por: Lüchtenborg, Margreet, et al.
Publicado: (2014)

Feasibility study of in vitro drug sensitivity assay of advanced non-small cell lung adenocarcinomas
por: Papp, Emoke, et al.
Publicado: (2020)

Factors influencing the utilization of prophylactic cranial irradiation in patients with limited-stage small cell lung cancer
por: Lok, Benjamin H., et al.
Publicado: (2017)

Association between time-to-treatment and outcomes in non-small cell lung cancer: a systematic review
por: Hall, Helen, et al.
Publicado: (2022)

Virtual bronchoscopic navigation combined with endobronchial ultrasound to diagnose small peripheral pulmonary lesions: a randomised trial
por: Ishida, Takashi, et al.
Publicado: (2011)

Navigating Diagnostic and Treatment Decisions in Non‐Small Cell Lung Cancer: Expert Commentary on the Multidisciplinary Team Approach
por: Popat, Sanjay, et al.
Publicado: (2020)

Modeling the Cost-Effectiveness of Adjuvant Osimertinib for Patients with Resected EGFR-mutant Non-Small Cell Lung Cancer
por: Lemmon, Christopher A, et al.
Publicado: (2022)

Pembrolizumab Every 6 Weeks Versus Every 3 Weeks in Advanced Non-Small Cell Lung Cancer
por: Dubé-Pelletier, Maude, et al.
Publicado: (2023)

Lung cancer specialists' opinions on treatment for stage I non-small cell lung cancer: A multidisciplinary survey
por: Lammers, Austin, et al.
Publicado: (2018)

White Blood Cells in Patients Treated with Programmed Cell Death-1 Inhibitors for Non-small Cell Lung Cancer
por: Sibille, A., et al.
Publicado: (2021)

Persisting Gaps in Optimal Care of Stage III Non-small Cell Lung Cancer: An Australian Patterns of Care Analysis
por: Woodford, Katrina, et al.
Publicado: (2022)

The Accuracy of Clinical Staging of Stage I-IIIa Non-Small Cell Lung Cancer: An Analysis Based on Individual Participant Data
por: Navani, Neal, et al.
Publicado: (2019)

Treatment Paradigms for Advanced Non‐Small Cell Lung Cancer at Academic Medical Centers: Involvement in Clinical Trial Endpoint Design
por: Aggarwal, Charu, et al.
Publicado: (2017)

Value of Precision Medicine in Advanced Non‐Small Cell Lung Cancer: Real‐World Outcomes Associated with the Use of Companion Diagnostics
por: John, Ani, et al.
Publicado: (2020)

Real-World Efficacy and Tolerability of Brigatinib in Patients with Non-Small Cell Lung Cancer with Prior ALK-TKIs in the United States
por: Jahanzeb, Mohammad, et al.
Publicado: (2022)

Arterial and Venous Thromboembolism in ALK-Rearrangement-Positive Non-small Cell Lung Cancer: A Population-Based Cohort Study
por: Icht, Oded, et al.
Publicado: (2023)

Accuracy of transbronchial biopsy as a rebiopsy method for patients with relapse of advanced non-small-cell lung cancer after systemic chemotherapy
por: Ishii, Hidenobu, et al.
Publicado: (2017)

Serum cytokine profiles and metabolic tumor burden in patients with non-small cell lung cancer undergoing palliative thoracic radiation therapy
por: Eide, Hanne A., et al.
Publicado: (2018)

PD‐1/PD‐L1 Blockade Therapy in Advanced Non‐Small‐Cell Lung Cancer: Current Status and Future Directions
por: Xia, Liliang, et al.
Publicado: (2019)

Incidence and Risk Factors for Pneumonitis Associated With Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer: A Single Center Experience
por: Altan, Mehmet, et al.
Publicado: (2023)

Health Equity in Patients Receiving Durvalumab for Unresectable Stage III Non-Small Cell Lung Cancer in the US Veterans Health Administration
por: Moore, Amanda M, et al.
Publicado: (2023)

Plasma Cell‐Free DNA Genotyping: From an Emerging Concept to a Standard‐of‐Care Tool in Metastatic Non‐Small Cell Lung Cancer
por: Gray, Jhanelle, et al.
Publicado: (2021)

Practical Guidance for the Management of Adverse Events in Patients with KRAS(G12C)-Mutated Non-Small Cell Lung Cancer Receiving Adagrasib
por: Zhang, Jun, et al.
Publicado: (2023)

Internal dose escalation is associated with increased local control for non-small cell lung cancer (NSCLC) brain metastases treated with stereotactic radiosurgery (SRS)
por: Abraham, Christopher, et al.
Publicado: (2017)

Application of liquid biopsy-based targeted capture sequencing analysis to improve the precision treatment of non-small cell lung cancer by tyrosine kinase inhibitors
por: Zhang, Lei, et al.
Publicado: (2022)

Adherence to National Comprehensive Cancer Network ALK Testing Guidelines for Patients with Advanced Non‐Small Cell Lung Cancer in U.S. Community Medical Centers
por: Bernicker, Eric H., et al.
Publicado: (2021)

Outcomes of Combination Platinum-Doublet Chemotherapy and Anti-PD(L)-1 Blockade in KRAS(G12C)-Mutant Non-Small Cell Lung Cancer
por: Elkrief, Arielle, et al.
Publicado: (2023)

The prognostic significance of aldehyde dehydrogenase 1A1 (ALDH1A1) and CD133 expression in early stage non-small cell lung cancer
por: Alamgeer, Muhammad, et al.
Publicado: (2013)

A Randomized Phase II Study of Metformin plus Paclitaxel/Carboplatin/Bevacizumab in Patients with Chemotherapy‐Naïve Advanced or Metastatic Nonsquamous Non‐Small Cell Lung Cancer
por: Marrone, Kristen A., et al.
Publicado: (2018)

Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Patients with Non-Small Cell Lung Cancer Resistant or Refractory to Immune Checkpoint Inhibitors
por: Barlesi, Fabrice, et al.
Publicado: (2022)

Differential clinicopathological features, treatments and outcomes in patients with Exon 19 deletion and Exon 21 L858R EGFR mutation-positive adenocarcinoma non-small-cell lung cancer
por: Batra, Ullas, et al.
Publicado: (2023)

Uptake of minimally invasive surgery and stereotactic body radiation therapy for early stage non-small cell lung cancer in the USA: an ecological study of secular trends using the National Cancer Database
por: Blom, Erik F, et al.
Publicado: (2020)

Impact of High-Grade Patterns in Early-Stage Lung Adenocarcinoma: A Multicentric Analysis
por: Bertoglio, Pietro, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_4n8l9m5kgcg328bdrg9r3e576p